Science Leads, Innovation Follows.

We partner with pioneering entrepreneurs who push the boundaries of science. Together, we pursue major leaps forward, not incremental advances. Whether it is first-in-class therapeutics or ground-breaking technology platforms, we seek opportunities with the potential to transform people’s lives.

The Path We Walk

As a dedicated life science venture firm, Red Tree employs a West Coast-centric, early stage-biased investment strategy. We focus primarily on entrepreneurs developing first-in-class and/or best-in-class therapeutics addressing significant unmet needs in the areas of oncology, neurology, and immunology.

We are deeply connected to the West Coast life science ecosystem with unique access to scientific luminaries and serial entrepreneurs at the region’s premier academic and research institutions. The strong relationships we have cultivated with our board of renowned and uniquely engaged scientific advisors allow us early access for sourcing the most promising innovation from these biotech hotbeds.

Proven Leadership

Accomplished team with decades of combined experience investing in, founding and operating life science companies across various stages, sectors and therapeutic areas. Together, we have compiled a track record of exceptional financial returns driven by a talent for translating scientific innovation into successful businesses.

Testimonals

Red Tree Venture Capital has been instrumental in Excellergy’s growth—supportive, strategic, and consistently aligned with our mission. From the seed round to our $70M Series A, they have demonstrated the type of partnership every team hopes for. Their confidence in our vision and steadfast collaboration have enabled us to achieve optimal outcomes for the company and the patients we ultimately serve."

Todd Zavodnick, CEO, Excellergy

Heath and the Red Tree team have been great partners across the board. We have greatly benefited from the deep network of investors and advisors that the Red Tree team knows."

Claire Mazumdar, CEO, Bicara Therapeutics

It has been very beneficial to be connected to some of the highly experienced advisors that the Red Tree teamwork with particularly for CMC and Clinical Development."

Ryan Cohlhepp, COO, Bicara Therapeutics

From the very beginning of our Series A fundraising conversations, Red Tree has been a valuable thought-partner as we build Rondo. The RT team has deep experience in drug development, so they know which areas require the most focus. They know where to trust our expertise as founders, where their experience and connections can add value, and which risks are the most significant at different stages of company growth. Red Tree has assembled a top-caliber team, and I can genuinely say we are enjoying building Rondo together."

Nathan Trinklein, Co-Founder and Chief Scientific Officer, Rondo Therapeutics

I appreciate the Red Tree team and their enthusiasm for leading Rondo’s Series A financing. They dug deeply into the science and got to know our team, then made the leap because they believed in us and the plan. Once they built conviction around the Rondo story, they did not need to wait for another investment group to jump first. Since their investment, the Red Tree team members have been excellent partners, supporting our growth by focusing on the big picture rather than minute details. I look forward to working with them for many years to come."

Shelley Force Aldred, Co-Founder and CEO, Rondo Therapeutics

I want to express my heartfelt gratitude to the entire Red Tree team, and especially to Heath. When Heath was at TPG and made the decision to invest in Ceribell initially, we were generating only a few thousand dollars in revenue and were active in just 10 hospitals. Many VCs turned us down, but Heath not only saw the potential but also provided invaluable support at every stage—from providing support through every fundraising round to critical decision-making. Heath has guided us through countless key decisions as we navigated the IPO process. I can’t thank the Red Tree team enough for all your support."

Jane Chao, President, CEO, Co-Founder, and Director, Ceribell

Working with Jeremy and the Red Tree team has been exceptional. Their deep scientific insight, strategic guidance, and unwavering commitment to our mission have been instrumental in accelerating EBVio’s efforts to develop transformative therapies for autoimmune disease. Jeremy’s ability to rapidly understand complex biology, challenge assumptions thoughtfully, and build high-trust partnerships has made him an invaluable collaborator. We are grateful for Red Tree’s support and vision, and excited to continue advancing EBVio and our groundbreaking therapeutics together."

William Robinson, Co-Founder, EBVio

Engrail is very fortunate to have Red Tree as an investor in our oversubscribed Series B financing round. Their diligence was very thorough and Dr. Lukatch’s experience in GABA biology hastened their ability to connect the science to the medical and commercial opportunity and move the financing process along in a speedy manner. Dr. Lukatch’s tremendous track record in building successful biotech companies and creating value for shareholders and LPs is simply outstanding - our company and management team are honored to have him on the Board of Directors and guide us through our next chapter as we advance our medicines to address large unmet patient needs."

Vikram Sudarsan, President and CEO, Engrail Therapeutics

Magnus was founded on the belief that treatment for brain health conditions can be faster, more precise, and dramatically more effective. Red Tree has been an outstanding partner in helping bring that vision forward—serving not only as an investor, but as a trusted advisor and steady hand as we work to bring a new generation of neuromodulation therapies to patients around the world. We’re grateful for their ongoing partnership and look forward to building the future of brain health together."